These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 1753684)
1. Lipid changes in the nephrotic syndrome: new insights into pathomechanisms and treatment. D'Amico G Klin Wochenschr; 1991 Sep; 69(13):618-22. PubMed ID: 1753684 [TBL] [Abstract][Full Text] [Related]
2. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Vaziri ND Kidney Int; 2016 Jul; 90(1):41-52. PubMed ID: 27165836 [TBL] [Abstract][Full Text] [Related]
4. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Wheeler DC; Bernard DB Am J Kidney Dis; 1994 Mar; 23(3):331-46. PubMed ID: 8128933 [TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of hyperlipidemia in the nephrotic syndrome. Attman PO; Alaupovic P Am J Nephrol; 1990; 10 Suppl 1():69-75. PubMed ID: 2256478 [TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of lipid abnormalities in patients with nephrotic syndrome/proteinuria: clinical implications. Warwick GL; Packard CJ Miner Electrolyte Metab; 1993; 19(3):115-26. PubMed ID: 8232098 [TBL] [Abstract][Full Text] [Related]
7. Should hyperlipidemia in children with the nephrotic syndrome be treated? Querfeld U Pediatr Nephrol; 1999 Jan; 13(1):77-84. PubMed ID: 10100296 [TBL] [Abstract][Full Text] [Related]
8. The hyperlipidemia of the nephrotic syndrome. Appel GB; Valeri A; Appel AS; Blum C Am J Med; 1989 Nov; 87(5N):45N-50N. PubMed ID: 2486547 [TBL] [Abstract][Full Text] [Related]
9. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome. Hu P; Lu L; Hu B; Du PF Scand J Clin Lab Invest; 2009; 69(6):680-6. PubMed ID: 19468931 [TBL] [Abstract][Full Text] [Related]
10. [Lipoproteins, apolipoproteins, lipoprotein lipase, hepatic triglyceride lipase and lecithin cholesterol acyltransferase in patients with nephrotic syndrome]. Breier C; Lisch HJ; Drexel H; Braunsteiner H Schweiz Med Wochenschr; 1983 Jun; 113(25):909-13. PubMed ID: 6612272 [TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering agents in proteinuric diseases. Appel GB; Appel AS Am J Nephrol; 1990; 10 Suppl 1():110-5. PubMed ID: 2256470 [TBL] [Abstract][Full Text] [Related]
12. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. de Sain-van der Velden MG; Kaysen GA; Barrett HA; Stellaard F; Gadellaa MM; Voorbij HA; Reijngoud DJ; Rabelink TJ Kidney Int; 1998 Apr; 53(4):994-1001. PubMed ID: 9551409 [TBL] [Abstract][Full Text] [Related]
13. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788 [TBL] [Abstract][Full Text] [Related]
14. A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cytokines in rats with chronic nephrotic syndrome. Tovar AR; Murguía F; Cruz C; Hernández-Pando R; Aguilar-Salinas CA; Pedraza-Chaverri J; Correa-Rotter R; Torres N J Nutr; 2002 Sep; 132(9):2562-9. PubMed ID: 12221209 [TBL] [Abstract][Full Text] [Related]
15. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? Keane WF; St Peter JV; Kasiske BL Kidney Int Suppl; 1992 Oct; 38():S134-41. PubMed ID: 1405364 [TBL] [Abstract][Full Text] [Related]